Women First: Preconception Maternal Nutrition (WF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01883193 |
Recruitment Status :
Completed
First Posted : June 21, 2013
Last Update Posted : July 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Maternal Malnutrition Growth Failure Mortality Morbidity Stunting | Dietary Supplement: Comprehensive Maternal Nutrition Intervention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7374 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Women First: Preconception Maternal Nutrition |
Study Start Date : | August 2013 |
Actual Primary Completion Date : | March 30, 2017 |
Actual Study Completion Date : | March 30, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1: Preconception
Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
|
Dietary Supplement: Comprehensive Maternal Nutrition Intervention
The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
Other Names:
|
Experimental: Arm 2: Pregnancy
Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
|
Dietary Supplement: Comprehensive Maternal Nutrition Intervention
The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
Other Names:
|
No Intervention: Arm 3: Control
Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
|
- Neonatal linear growth [ Time Frame: <24 hours of age ]Research assistants will obtain neonatal length measurement at <24 hours of age.
- Length-for-age Z-scores [ Time Frame: age 0.5, 1, 3, 6, 12, 18 and 24 months postnatal ]Research assistants will obtain infant anthropometry measurements, which include length, head circumference, triceps skin folds, Mid Upper Arm Circumference (MUAC), and weight, at age 0.5, 1, 3, 6, 12, 18 and 24 months of age. Length-for-age Z-scores will be compared for offspring of mothers randomized to the three intervention arms.
- Estimate fetal growth [ Time Frame: 12 weeks gestation ]Ultrasound measurements will be undertaken at 12 weeks gestation with the goals of confirming gestational age and estimating fetal growth.
- Mean birth weight [ Time Frame: at birth ]As a dichotomous variable, the cutoff of 2500 g does not have the power of the continuum of birth length, but is included because of the long history of use in determining which newborns are severely underweight and this association with impaired neonatal and long-term prognosis. The design of this study will allow distinction between pre-term birth (PTB) and growth retardation of the term infant (mature IUGR).
- Incidence of low birth weight (LBW) infants [ Time Frame: at birth ]As a dichotomous variable, the cutoff of 2500 g does not have the power of the continuum of birth length, but is included because of the long history of use in determining which newborns are severely underweight and this association with impaired neonatal and long-term prognosis. The design of this study will allow distinction between pre-term birth (PTB) and growth retardation of the term infant (mature IUGR).
- Perinatal Mortality [ Time Frame: From 20 weeks gestation through 1 month of age ]The outcome is to determine, in poor food insecure communities if a daily comprehensive maternal nutrition supplement starting ≥ 3 months preconception and continuing throughout pregnancy will reduce the incidence of offspring perinatal mortality (including still births), compared with that for offspring of mothers who commence the same supplement starting at 12-16 weeks gestation.
- Incidence of severe neonatal and infant infectious disease [ Time Frame: birth to 6 months of age ]Outcome measure is number of acute visits / admissions to health center/hospital for severe infectious disease. This secondary outcome will provide insight into the importance of maternal and fetal nutrition in the early prenatal development of host-defense mechanisms and, through comparison with the prenatal and control Arms, on the importance of maternal nutrition throughout pregnancy. It is further intended to collect minor morbidity data.
- Epigenome (Maternal) [ Time Frame: baseline, 12 and 34 weeks gestation, delivery, and 3 months postpartum (maternal); 2 weeks and 3 months of age (infant) ]To compare longitudinal changes between groups in the maternal epigenome (including blood, buccal swabs, and possibly other readily obtainable samples) at baseline, 12 weeks pregnancy (prior to initiation of LNS in Arm 2), 34 weeks pregnancy, and at 3 months postpartum. Also will collect placental, fetal and cord blood epigenome at delivery by group and infant epigenome at 3 months with fingerstick blood and buccal swabs.
- Epigenome (Infant) [ Time Frame: 2 weeks and 3 months of age ]To compare longitudinal changes between groups in the maternal epigenome (including blood, buccal swabs, and possibly other readily obtainable samples) at baseline, 12 weeks pregnancy (prior to initiation of LNS in Arm 2), 34 weeks pregnancy, and at 3 months postpartum. Also will collect placental, fetal and cord blood epigenome at delivery by group and infant epigenome at 3 months with fingerstick blood and buccal swabs.
- Deep phenotyping of maternal metabolic and nutritional status [ Time Frame: 12 and 34 weeks gestation, delivery, and 3 months postpartum ]The outcome represents deep phenotyping by measuring in maternal tissues: hormones, metabolites, measures of inflammation, oxidant stress and immune function/status, and nutrient biomarkers as possible indices of fundamental metabolic alterations resulting from improved long-term maternal nutrition in food insecure populations. Longitudinal blood samples will be collected from maternal participants in Arms 1 and 2 at baseline, 12 weeks gestation (prior to initiation of LNS in Arm 2), 34 weeks gestation, delivery and 3 months postpartum. Samples will also be collected from participants in Arm 3 at 34 weeks gestation and at 3 months postpartum.
- Microbiome (maternal) [ Time Frame: 12 & 34 weeks gestation and delivery (maternal) ]Based on potential long-term effects on maternal nutritional and metabolic state from preconception intervention, we hypothesize that the gut microbiota will differ between the two intervention arms at the three proposed time points.
- Microbiome (infant) [ Time Frame: 14 days and 3 months of age (infant) ]Based on potential long-term effects on maternal nutritional and metabolic state from preconception intervention, we hypothesize that the gut microbiota will differ between the two intervention arms at the three proposed time points.
- Composition of breast milk [ Time Frame: 14 days postpartum ]We hypothesize that improved maternal nutrition at the time of greatest plasticity in early pregnancy will favorably influence maternal metabolic and nutritional status throughout pregnancy and thus potentially the composition of breast milk in terms of hormonal content, immune factors, cytokines, and gut growth factors.
- Neurodevelopment assessment [ Time Frame: 24 mo age ]Offspring randomized to receive neurodevelopmental evaluation (BSID-III or InterNDA, 2:1 ratio) at 24 mo of age
- Gestational weight gain (GWG) [ Time Frame: Enrollment to delivery ]Describe GWG and its associations with fetal growth and birth outcomes within each country by baseline maternal nutritional status (BMI) and the receipt of nutrition interventions. Evaluate how GWG might mediate the effects of maternal nutrition interventions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 35 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 16-35 years of age;
- expectation to have first or further pregnancy without intent to utilize contraception
- Hb >8 g/dL
Exclusion Criteria:
- Nulliparous women who do not agree to hospital delivery (equipped for caesarian section) or/and do not have ready access to such a facility.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01883193
Congo, The Democratic Republic of the | |
Kinshasa School of Public Health | |
Kinshasa, Congo, The Democratic Republic of the | |
Guatemala | |
INCAP | |
Guatemala City, Guatemala | |
India | |
Jawaharlal Nehru Medical College | |
Belgaum, India, 590 010 | |
Pakistan | |
Aga Khan University | |
Karachi, Pakistan |
Principal Investigator: | Nancy Krebs, MD,MS | University of Colorado, Denver | |
Principal Investigator: | Michael Hambidge, MD, SciD | University of Colorado, Denver |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Colorado, Denver |
ClinicalTrials.gov Identifier: | NCT01883193 |
Other Study ID Numbers: |
12-1672 OPP1055867 ( Other Grant/Funding Number: Bill & Melinda Gates Foundation ) U10HD076474-01 ( U.S. NIH Grant/Contract ) |
First Posted: | June 21, 2013 Key Record Dates |
Last Update Posted: | July 8, 2021 |
Last Verified: | July 2021 |
preconception maternal nutrition LBW Length-for-age maternal nutrition supplement |
multi-micronutrient fortified lipid-based supplement infant growth low-resource settings |
Malnutrition Failure to Thrive Nutrition Disorders Micronutrients Physiological Effects of Drugs |